ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer ABV-1504 has completed Phase II clinical trials for major depressive disorders ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.